Sullivan Balances Appili’s Risks

Pathogens’ growing antibiotic resistance is a global concern. Halifax drug discovery firm Appili Therapeutics Inc. is developing its own solutions, and scouring the world for potential drugs with which to grow the company.
CEO Kevin Sullivan said since Appili formed last year, its strategy has been to balance risk by acquiring drug candidates at different stages of development.
“Our strategy is